The use of generative artificial intelligence (AI) in clinical trial recruitment is rapidly changing how participants are identified, engaged, and enrolled. While the technology promises efficiency and broader reach, it also raises urgent ethical concerns. First, algorithmic bias in recruitment systems may reproduce or deepen health disparities, threatening efforts to build representative and inclusive clinical studies. Second, reliance on AI-generated patient materials complicates informed consent and transparency, since tailored outputs can obscure critical risks, oversimplify complex medical information, or frame participation in ways that undermine trust. Third, the integration of AI into recruitment workflows necessitates enhanced frameworks for accountability and responsible governance. Unlike traditional recruitment processes, generative AI involves layers of opacity, raising difficult questions about responsibility for errors, bias, and participant harm. Without strong regulatory oversight, the rapid adoption of AI-driven tools risks undermining participant protections and public trust in clinical research.
 
Kalina Kamenova PhD is Founder and Research Director of Canadian Institute For Genomics And Society | Toronto. Her work integrates bioethics, science policy, and public engagement strategies to shape evidence-based decisions in health and biomedical innovation, including genomics, precision medicine, stem cell and regenerative therapies, and artificial intelligence (AI) in healthcare. As Founder and Research Director of the Canadian Institute for Genomics and Society (Genomics4S), I have advanced participatory research, ethical governance, and policy innovation in emerging biotechnologies. Partnering with leading researchers, scientists, policymakers, and industry stakeholders, I have enabled strategic collaboration on initiatives that navigate the ethical and societal dimensions of biomedical innovation. With prior leadership experience at Loyalist College’s Applied Research and Innovation Office and University of Alberta’s Centre for Public Involvement, I have also contributed to fostering cross-sectoral innovation through applied research, policy development, and strategic partnerships. My executive and management expertise spans research administration, grant development, research ethics, team-building, and stakeholder engagement. I am driven by a commitment to responsible research and innovation, ensuring inclusive public discourse around transformative scientific advancements.

Other Posts

The new HIV prevention drug lenacapavir is beginning to reach communities in Zambia, offering new hope in the global fight against HIV. Administered just twice a year, the injectable medication has demonstrated near-complete effectiveness in [...]

A new study published in the New England Journal of Medicine found that bepirovirsen, an experimental hepatitis B treatment, achieved a functional cure in about 1 in 5 patients with chronic hepatitis B after a [...]

  • map of virus concentration

As an Ebola disease outbreak continues in the Democratic Republic of the Congo and Uganda, the WHO has identified several promising treatments and vaccines for further study. Experts are prioritizing a select group of therapies [...]

AI has been used to generate hypotheses and identify targets in drug discovery teams. Though AI is still not able to fully carry out tests and data analysis for all research applications, it has a [...]

  • Solidarity in Global Health Crises

The World Health Organization (WHO) is expected to provide an update after declaring the Ebola outbreak in the Democratic Republic of the Congo a global public health emergency. There have been over 390 suspected Ebola [...]

  • in vitro fertilization

Although in vitro fertilization (IVF) has helped many people conceive since the birth of the first IVF baby, the process remains difficult and is not always successful. The field is now exploring using AI, robotics, [...]